arrow
A

Andrea Fontana

eth zurich
H指数:27
被引数:2,220

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
2024-12-180
OA
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study
2024-12-011
PRE
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
2024-09-012
OAAI
HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+and IHC 3+populations
2024-05-020
PRE
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (vol 9, 73, 2023)
2024-02-050
OAAI
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (vol 9, 89, 2023)
2023-10-301
OAAI
Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
2023-10-011
PRE
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
2023-09-086
OAAI
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study
2023-08-270
OAAI
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
2023-07-283
OAAI
Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort
2023-03-010
PRE
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
BREAST
IF7.9
2022-12-0115
OAAI
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
2022-03-215
OAAI
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

转移性三阴性乳腺癌 (TNBC) 患者的节拍化疗 (mCHT): VICTOR-6研究的结果

2021-09-219
OAAI